Oculis Holding AG (OCS) Share-based Compensation (2022 - 2026)
Oculis Holding AG (OCS) recorded quarterly Share-based Compensation of $6.4 million in Q1 2026, up 18.37% quarter-over-quarter from $5.4 million in Q4 2025, and up 118.32% on a YoY basis from $2.9 million in Q1 2025.
Oculis Holding AG (OCS) Share-based Compensation (2022 - 2026) Analysis & Trends
Oculis Holding AG's Share-based Compensation history runs 5 years deep, the most recent figure standing at $6.4 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 118.32% year-over-year to $6.4 million; the TTM figure through Mar 2026 stood at $23.0 million (up 80.81% YoY), while the FY2025 annual figure was $20.1 million, up 79.77% from the prior year.
- Share-based Compensation was $6.4 million for Q1 2026 at Oculis Holding AG, up from $5.4 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $6.4 million in Q1 2026 to a low of $150513.2 in Q4 2022.
- Historically, Share-based Compensation has averaged $2.8 million across 5 years, with a median of $2.9 million in 2024.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation soared 733.86% in 2024, then jumped 50.32% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $150513.2 in 2022, then soared by 680.47% to $1.2 million in 2023, then jumped by 176.17% to $3.2 million in 2024, then surged by 66.3% to $5.4 million in 2025, then grew by 18.37% to $6.4 million in 2026.
- The last three Share-based Compensation figures came in at $6.4 million (Q1 2026), $5.4 million (Q4 2025), and $5.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 305,000.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 26.47 Mn |
| 10 | Oculis Holding AG | 8.23 Bn | 7.92 Bn | - | 6.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.39 Mn |
| Mar 31, 2026 | 6.39 Mn |
| Dec 31, 2025 | 5.40 Mn |
| Dec 31, 2025 | 5.40 Mn |
| Sep 30, 2025 | 5.70 Mn |
| Sep 30, 2025 | 5.70 Mn |
| Jun 30, 2025 | 5.48 Mn |
| Jun 30, 2025 | 5.48 Mn |
| Mar 31, 2025 | 2.93 Mn |
| Mar 31, 2025 | 2.93 Mn |
| Dec 31, 2024 | 3.24 Mn |
| Dec 31, 2024 | 3.24 Mn |
| Sep 30, 2024 | 2.89 Mn |
| Sep 30, 2024 | 2.89 Mn |
| Jun 30, 2024 | 3.65 Mn |
| Jun 30, 2024 | 3.65 Mn |
| Mar 31, 2024 | 1.31 Mn |
| Mar 31, 2024 | 1.31 Mn |
| Dec 31, 2023 | 1.17 Mn |
| Dec 31, 2023 | 1.17 Mn |